Core Viewpoint - The company announced that its wholly-owned subsidiary, Harbin Kuaihua Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration regarding the application for the registration and marketing authorization of Clobetasol Propionate Ointment, which is intended for local treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] Group 1 - The product is classified as a Class 4 chemical drug [1] - The drug review process is lengthy and involves multiple steps, leading to uncertainty regarding the completion time and approval results [1] - The company will actively promote the marketing authorization process for this product and will continue to monitor the approval status, ensuring timely information disclosure [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for a new chemical raw material drug, indicating a significant development in its product pipeline [1] Group 1: Company Developments - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" from the National Medical Products Administration [1] - The approved chemical raw material is named Clobetasol, which is a phosphodiesterase 4 (PDE-4) inhibitor [1] - Clobetasol ointment is indicated for local external treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Clobetasol [1] Group 1: Company Information - Clobetasol is a phosphodiesterase 4 (PDE-4) inhibitor, indicated for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] - The company has 22 competitors in China with A registration status for Clobetasol raw materials [1] Group 2: Market Data - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Clobetasol, a PDE-4 inhibitor, for treating mild to moderate atopic dermatitis in patients aged 3 months and older [1] Group 1: Company Developments - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for the marketing application of Clobetasol [1] - Clobetasol ointment is specifically indicated for local external treatment of atopic dermatitis [1] Group 2: Market Insights - There are currently 22 companies in China with A registration status for Clobetasol raw materials [1] - According to IMS data, the global sales figures for Clobetasol formulations are projected to be $224 million in 2022, $206 million in 2023, and $196 million in 2024 [1] - The consumption of Clobetasol raw materials is expected to be 706.68 kg in 2022, 963.57 kg in 2023, and 1118.43 kg in 2024 [1]

Group 1 - The company achieved a revenue of 1.79 billion yuan in the raw materials and additives business during the first half of the year, with hyaluronic acid raw material sales reaching 1.16 billion yuan, a year-on-year increase of 23.4% [3] - The pharmaceutical business generated a revenue of 207 million yuan, with over 200 new county-level and OTC customer developments, focusing on core product upgrades [2] - The cosmetics segment reported a revenue of 1.094 billion yuan, with the Yilian brand achieving a revenue of 554 million yuan, reflecting a year-on-year growth of 23.78% [2] Group 2 - The company launched over 80 new products in the cosmetics sector, including the "Yier Doctor 287 mask" and "Yilian Purple Light Dual Extract Essence Water" [3] - The company has made significant advancements in technology, such as the innovative permeable collagen technology, which increased collagen subcutaneous penetration by 27.5 times [3] - The company is actively developing the "food and medicine homologous" business and has established cooperation with major clients to enhance raw material supply [2]